Ixazomib Rollover Study
NCT02924272 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2025-03-12
Summary
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
Conditions
- Multiple Myeloma
- Lymphoma
- Amyloidosis
Interventions
- DRUG
-
Ixazomib
Ixazomib Capsules
Sponsors & Collaborators
-
Takeda Development Center Americas, Inc.
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Medical Director · Takeda
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-12-16
- Primary Completion
- 2024-07-03
- Completion
- 2024-07-03
- FDA Drug
- Yes
Countries
- United States
- Belgium
- Canada
- China
- Greece
- Japan
- Poland
- Singapore
- South Korea
- Spain
- Sweden
Study Locations
More Related Trials
-
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
NCT02628405 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
NCT03372837 ·Status: COMPLETED ·Phase: PHASE3
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
NCT02160015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
NCT02924402 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
NCT03321643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054 ·Status: RECRUITING ·Phase: PHASE1
-
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
NCT01729806 ·Status: COMPLETED ·Phase: PHASE1
-
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
NCT02960555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
NCT00294632 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05221645 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
NCT01542918 ·Status: COMPLETED ·Phase: PHASE1
-
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
NCT02446457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
NCT02955589 ·Status: COMPLETED ·Phase: PHASE2
-
AZA Combined with R-GemOx for Elderly DLBCL Patients
NCT06778902 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
NCT03232307 ·Status: WITHDRAWN ·Phase: PHASE2
-
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00005592 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
NCT00022971 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
NCT06213311 ·Status: RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06609304 ·Status: RECRUITING ·Phase: PHASE4
-
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02760485 ·Status: COMPLETED ·Phase: PHASE1/PHASE2